Curis, a biotech company developing the drug emavusertib for cancer treatment, will announce its first quarter 2026 financial and operating results on May 12, 2026. The company will hold a conference call and webcast to discuss these results. Emavusertib is being tested in clinical trials for lymphoma, chronic lymphocytic leukemia, and acute myeloid leukemia, with orphan drug designations from the FDA and European Commission. This update is important for investors tracking Curis's progress in cancer drug development and financial health.
The global silicon interposer market, valued at $4 billion in 2025, is projected to grow to $14.04 billion by 2035 with a CAGR of 13.38%. Growth is fueled by rising adoption of AI, chiplet architectures, and advanced semiconductor packaging technolog...
The AI in spintronics market is projected to grow from $2.42 billion in 2026 to $7.11 billion by 2030, expanding at a CAGR of 30.9%. Growth is fueled by AI integration in spintronic design, demand for energy-efficient memory, and advances in magnetic...
The global wax market, valued at $11.26 billion in 2025, is projected to grow to $16.65 billion by 2035 at a CAGR of 3.99%. Growth is fueled by rising demand in packaging, cosmetics, candle making, adhesives, and industrial uses, with natural waxes l...
Basel Medical Group Ltd announced it has regained compliance with Nasdaq's minimum bid price rule after its share price stayed at or above $1.00 for 10 consecutive business days ending July 7, 2026. The company was previously notified in January 2026...
BingX, a major crypto exchange, introduced the BingX Visa Debit Card in partnership with Wirex, allowing users to spend digital assets globally through Visa's payment network. The card supports purchases, ATM withdrawals, and automatic currency conve...
